Auyeung, Diana J., PhD. As a Toxicologist, Dr. Auyeung has dabbled in the many facets starting with receiving a minor in Environmental Toxicology (major Chemistry) from University of California at Davis in 1993. She then worked as a human health risk assessor for an Environmental Consulting firm until 1997. Dr. Auyeung then returned to academia and received her Doctoral degree at Virginia Commonwealth University Department Pharmacology and Toxicology focusing on Molecular Toxicology in 2002. Since graduating, she has been working at Charles River Laboratories as a Study Director, specializing in Non-human Primate Reproductive Toxicology. Dr. Auyeung has been actively involved in American Chinese toxicology communities; and currently as a member of the Joint Working Group to facilitate the merging of ACTS and ACSOT. For the past two years, her biggest contributions have been maintaining the AACT website, directory and E-mail distribution list to increase the dissemination of AACT communications. Additionally, she has been involved in drafting the AACT By-laws and reviewing applications for the Best Paper and Best Abstract award.

Fu, Li-jie, PhD, MPH. Dr. Li-jie Fu is the President of Next Century Incorporated, a contract research organization (CRO) offering testing services for discovery and regulatory GLP compliance. He has been in the field of toxicology for more than twenty years and has a wealth of experience in the operation of a CRO and a sound knowledge of GLP regulations and practices. Prior to Next Century, Dr. Fu worked for years as a Study Director at DuPont Central Research & Development and received his GLP training and experience in the late 1980s. In 1994, he has co-founded Next Century Incorporated, a full GLP compliant laboratory. He has also been working for WHO as an expert on Safety Evaluation and GLP Regulation. As early as 1996, Dr. Fu has given presentations on GLPs to the scientific community in China. He also provides his advice to several start-up CRO (GLP labs) in China. Dr. Fu has edited four books and authored over 60 articles and book chapters. He has been an advisory board member of the Chinese J. of Pharmacolgy & Toxicology, an editorial board member of the J. of Hygiene Research, and a reviewer for numerous other scientific journals. He was a former president and board member of ACSOT and is a member of the Joint Working Group, current Board Director of the Chinese Society of Toxicology, and a life-member of SAPA and many other scientific associations.

Kang, James Y., DVM, PhD, FATS. Dr. Kang is a Professor and Distinguished University Scholar at the University of Louisville. He obtained a Ph.D. at Iowa State University in 1989 and become an Assistant Professor of Pharmacology and Toxicology at the University of North Dakota School of Medicine in 1991, Associate Professor and University Scholar in 1996, then Professor (2001-) and Distinguished University Scholar (2003-) at the University of Louisville School of Medicine. Dr. Kang has been a full member of numerous professional associations and an elected Fellow of the Academy of Toxicological Sciences (2001-). Dr. Kang has also served as the Editor-in-Chief of *Cardiovascular Toxicology* and the Editor of Methods in Pharmacology and Toxicology book series, and Associate Editor for *Experimental Biology and Medicine* and *Journal of Health Science*. Dr. Kang is the President (2005) of the Ohio Valley SOT and Secretary and Treasurer (2003-2004) of the Toxicology Division of ASPET. Dr. Kang has served as a Member of NIH study sections, member of VA cardiovascular study section, and in many scientific grant application review committee. His research interests include molecular mechanisms of cardiotoxicity, oxidative and metal regulation of metallothionein and its antioxidant function, alcoholic liver injury and prevention and treatment of liver fibrosis. Dr. Kang served as the president of ACTS and is currently a Co-Chair of the Joint Working Group of AACT.

Li, Li, PhD, DABT. Dr. Li is currently a principal scientist at Aventis Pharmaceuticals. His main responsibility is to serve as project team representative for the department of drug safety evaluation (DSE), and to plan and coordinate preclinical safety studies to support clinical trials and drug registration. He has participated in many IND/NDA submissions and has been an author for numerous study reports and scientific publications. Dr. Li received his Ph.D. and MS in toxicology from University of Texas - Houston School of Public Health, and his BS degree in Biochemistry from Wu Han University in China. He acquired his post-doctoral training at University of Texas Houston Medical School and in R W J Pharmaceutical Research Institute (J&J). Dr. Li has been working in pharmaceutical industry for 7 years. Dr. Li served as a board member of ACSOT.

Pei, Luqi, PhD, DMV. Dr. Luqi Pei is a pharmacologist and toxicologist at the US Food and Drug Administration (USFDA). He specializes at the nonclinical safety evaluation of inhaled drug products. He has reviewed numerous IND/NDA and is an author for many scientific publications. Dr. Pei received his Ph.D. from the Texas A&M University College of Medicine, M.S. from the Colorado State University and DVM from the Gansu University of Agriculture, China. He completed his postdoctoral training at the Lovelace Inhalation Toxicology Institute, Albuquerque, NM. Prior to his graduate training, Dr. Pei was a visiting scientist at the Colorado State University and a faculty member at the Gansu Agriculture University. He also worked in the pharmaceutical industry for a year. Dr. Pei served as a board member and Secretary of ACSOT.

Qiao, Guilin, DVM, PhD. Dr. Qiao earned his DVM (82), MS (85) and PhD (89, South China Agri Univ) in Pharm/Tox with expertise in dermal toxicology and PK-PD modeling. Dr. Qiao is currently a Pharmacologist at US Food and Drug Administration (2001-) and an Associate Professor (Adj.) of West Virginia Univ (99-). He conducts regulatory reviews of new animal drug applications while concurrently directing research projects at FDA. Prior to his tenure at FDA, he served as a Team Leader in NIOSH/CDC conducting occupational dermal Tox studies (98-2001). He did his PostDoc training (90-95) before jointing the faculty as a Res Assist Prof, (95-98) in NC State Univ. Dr. Qiao has been a Grant Review Panelist of DoD/AIBS since 1999 and served as a manuscript/guideline reviewer for many journals and regulatory agencies. Dr. Qiao's dermal Tox and modeling research has been well founded extramurally (over $4.6M since 95) and well published. In addition to full memberships in many societies, Dr. Qiao has served the Tox community as one of the initial organizers to establish and then Committee Chairs of the DermTox Specialty Section of SOT (2000-), Vice President of ACTS (2004-), and a member of the Joint Working Group of our new AACT.

Tian, Baohong, PhD, DABT. Dr. Baohong Tian received her Doctorate in Pharmacology and Neuroscience from the University of Georgia and is a diplomat of the American Board of Toxicology. She joined the Southern Research Institute in 2001 as a Research Scientist and supervisor providing expertise for the operation of the Quantitative PCR Laboratory that will support biodistribution studies of gene vectors required for preclinical safety studies as well as gene expression studies. Dr. Tian's research has included pharmacology studies involved in the mechanism and function of the cardiovascular system; molecular biology studies involved in the phenotypic characterization of ACE knockout mice, and viral load analyses in support of clinical trials of HIV therapeutics. Dr. Tian has presented her research at several national meetings and has received several awards, including the Astra-Merck Young Investigator Award from Southern Society for Clinical Investigation and Henry Christian Award from American Federation for Medical Research Foundation. Dr. Tian has co-authored 25 papers and abstracts comprising studies on virology, molecular biology, and cardiovascular pharmacology. Dr. Tian served as a board member and Treasurer of ACSOT.

Wang, Charles Ying, PhD, DABT. Dr. Wang is currently a Principal Lead Scientist at Johnson & Johnson Pharmaceutical Research & Development, LLC. He received his BS in pharmacy from Beijing Medical College, his MS in pharmacology from Peking Union Medical College, and his PhD in toxicology from University of Illinois at Chicago. He completed his postdoctoral trainings at University of Iowa and Pharmacia & Upjohn, Inc. Dr. Wang was a Study Director at Biologic Safety Research, Inc. and MPI Research, LLC, and later joined Novartis Pharmaceuticals Corp. as a Study Director-Senior Scientist. Dr. Wang was involved in preparation of several INDs, IBs and CTX, and hundreds of toxicology study reports to support regulatory submission. He also has numerous scientific publications in peer-review journals. Dr. Wang is the former President of American-Chinese Society of Toxicology and currently a member of the Joint Working Group of AACT. He played an important role to facilitate the merger of ACSOT and ACTS and was involved in drafting the AACT By-law. He was one of the organizers of ACSOT-ACTS joined dinner in 2004 and AACT annual meeting in 2005. Dr. Wang believes that AACT should serve as a platform to promote communication among professionals in toxicology of Chinese ethnicity in US and make a contribution to the progress of toxicology in China.

Wang, Jiasheng, PhD. Dr. Jia-Sheng Wang has been a tenured associate professor of molecular toxicology in the Department of Environmental Toxicology, Texas Tech University and the principal research scientist at the Division of Human Health Sciences, The Institute of Environmental and Human Health, Texas Tech University System. He did his undergraduate studies in Preventive Medicine and further obtained Master Degree of Medicine in Food Toxicology from the Shanghai First Medical College in 1981. From 1982-1985 he served as director for toxicology laboratory, acting division leader for nutrition and food safety, and assistant dean fro research in Nanjing Railway Medical College. He worked as a visiting scientist from 1986 to 1991 at the Division of Toxicology, Massachusetts Institute of Technology. He obtained a PhD in pathology and immunology in 1994 from the Boston University. He then worked as a NIEHS postdoctoral fellow from 1994 to 1995 and served as research associate, senior research associate, and research assistant professor from 1995 to 1999 at the Division of Toxicological Sciences, Johns Hopkins School of Public Health. His current research projects focus on toxic and human health effects of biotoxins and natural products, chemical carcinogenesis, and cancer chemoprevention, which were financially supported by the NIH, DOD, and USAID. Dr. Wang has been the board member and the secretary for ACSOT since 2003.

You, Li, PhD. CIIT Centers for Health Research, North Carolina. Dr. You leads an active research lab at CIIT Centers for Health Research. His area of research is mammalian sexual and reproductive development and steroid hormone action. Dr. You has been an active participant in the activities of the Chinese American toxicology community for many years and has previously served as a board member and as the president of American Chinese Society of Toxicology (ACSOT). Dr. You played an active role in re-organizing ACSOT and ACTS into the current AACT. Dr. You currently is a member of the Joint Working Group of AACT. Dr. You believes that, in addition to serving as a platform for friendship and collaborations among its members, the new AACT should actively promote the interest of our growing community. Dr. You received his Ph.D. in Pharmacology and Toxicology from the University of Georgia and his medical education at Chongqing Medical College.

Zhang, Haizhou, PhD. DABT. Dr. Zhang is currently a senior scientist in the Toxicology and Safety Assessment Department of Boehringer Ingelheim Pharmaceuticals Inc. He works as a compound manager to oversee all safety evaluations of several classes of compounds being developed by Boehringer Ingelheim. Before he joined Boehringer Ingelheim in 2004, Dr. Zhang worked at Covance Laboratories Inc. as a Study Director primarily for genetic toxicology studies (2000-2004). From 1995 to 1996, Dr. Zhang worked as a toxicologist in the National Institute for the Control of Pharmaceutical and Biological Products in Beijing, China. He received his Ph.D. in Toxicology from Indiana University. He also has a MPH and a Bachelor of Medicine from Beijing Medical University. He is a certified Diplomat of American Board of Toxicology. Dr. Zhang is experienced with drug safety evaluation, cell transformation, oxidative stress and mechanisms of chemical carcinogenesis. He served as an expert for European Centre for the Validation of Alternative Methods (ECVAM). He is a member of SOT, Environmental Mutagen Society, and a board member of Genetic Toxicology Association. Dr. Zhang served as board member of ACSOT.

Zhang, Zhihua (John), PhD, MSPH. Dr. Zhang is an Associate Director and the Head of non-clinical Drug Safety Evaluation, Enzon Pharmaceuticals, NJ. Before joining Enzon, Dr. Zhang worked for Hoffmann-La Roche as a Sr. Principal Scientist responsible for designing and managing the toxicology programs for many drugs in research and development. He also worked for Knoll/Abbott as a Principal Investigator in toxicology with similar capacities. Prior to Knoll/Abbott, he worked for Colgate-Palmolive Company as a Sr. Research Scientist. Dr. Zhang has participated in many IND/NDA writings and submissions. Dr. Zhang obtained his Ph.D. in toxicology from Rutgers University/University of Medicine and Dentistry of New Jersey and performed his postdoctoral training in National Cancer Institute of NIH in Bethesda, MD. In addition to his Ph.D. in toxicology, Dr. Zhang also has a master of science in public health from University of California, Los Angeles and a medical degree from China. Dr. Zhang served as a board member, then president of ACSOT and played a very important role in the merger between ACSOT and ACTS and is a Co-Chair of the Joint Working Group of AACT.

Zhao, Qiyu (Jay), PhD, MPH. Dr. Zhao is a toxicologist in Toxicology Excellence for Risk Assessment (*TERA*). Dr. Zhao obtained his medical degree and Master in Public Health from Shanghai Medical University in 1989 and his Ph.D in Toxicology from University of Cincinnati, 1997. Before he joined *TERA*, he had had extensive experience in chemical toxicity evaluation, tumor epidemiology, pulmonary inflammation, and chemokine gene regulation. Since Dr. Zhao joined *TERA* in 1997, he has participated in preparing many risk assessment documents at *TERA*. As a project leader and principal author, he has managed and prepared several critical toxicity reviews and risk assessment documents for various U.S. government agencies, such as Environmental Protection Agency (EPA) and the National Institute for Occupational Safety and Health (NIOSH), as well as industrial groups. In addition, Dr. Zhao has extensive experience in developing and applying new risk assessment methodology including the new IPCS guidelines on chemical specific adjustment factors (CSAF), the EPA guidelines on assessment of chemical mixtures, and EPA benchmark dose technology. Dr. Zhao served as the vice president of ACSOT and is a member of the Joint Working Group of AACT.

Zheng, Wei, PhD. Dr. Zheng is an Associate Professor of Health Sciences at Purdue University. He currently serves as a member in NIH/Environmental Health Sciences Review Committee and in Editorial Boards of Cerebrospinal Fluid Research and of Toxicology Letters. He has chaired either the Continued Education Courses or Symposia in SOT annual meetings each year since 1999, and organized other international symposia. In addition, Dr. Zheng is the Chief Executive Officer of Life Plus, LLC, a toxicology and testing devices company based in Indiana. Dr. Zheng received his Ph.D. from the University of Arizona in Tucson. Prior to his tenure at Purdue, he was an Associate Professor in Columbia University in New York City between1993-2003. Dr. Zheng played a seminal role in establishing the very first Chinese students/scholars organization in toxicology in 1989, a part of which has since evolved to merge into the current organization. He served as the President of Association of Chinese Scholars and Students of Toxicology in America in 1991 and the Secretary of American Chinese Toxicologist Society (ACTS) in 1994.